Year: 2025
Type: article
Abstract: Mitochondria serve an essential metabolic and energetic role in cellular activity, and their dysfunction has been implicated in a wide range of disorders, including cardiovascular conditions, neurodegenerative disorders, and metabolic syndromes. Mitochondria-targeted therapies, such as Elamipretide (SS-31, MTP-131, Bendavia), have consequently emerged as a topic of scientific and clinical interest. Elamipretide has a unique structure allowing for uptake in a variety of cell types and highly selective mitochondrial targeting. This mitochondria-targeting tetrapeptide selectively binds cardiolipin (CL), a lipid found in the inner mitochondrial membrane, thus stabilizing mitochondrial cristae structure, reducing oxidative stress, and enhancing adenosine triphosphate (ATP) production. Preclinical studies have demonstrated the protective and restorative efficacy of Elamipretide in models of heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness. Clinical trials such as PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM elaborate on preclinical findings and highlight the significant therapeutic potential of Elamipretide. Further research may expand its application to other diseases involving mitochondrial dysfunction as well as investigate long-term efficacy and safety of the drug. The following review synthesizes current knowledge of the structure, mechanisms of action, and the promising therapeutic role of Elamipretide in stabilizing mitochondrial fitness, improving mitochondrial bioenergetics, and minimizing oxidative stress.
DOI: 10.3390/ijms26030944
Institution: Albert Einstein College of Medicine
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,499
Awards: G1000608447, G1107707869, G1196682224, G1214234794, G1218068299, Molecular regulation of skeletal muscle thermogenesis, G1413706045, G1512127578, G1530010185, Inositol 1,4,5-trisphosphate receptors and activation of cardiac fibroblasts in ischemia/reperfusion injury, G180476886, G186995139, G1899863491, Beta Cell Intracellular Calcium and Diabetes, G2001956217, Functional role of IP3 receptors in the regulation of cardiac myofibroblasts, G2252929418, G243246254, G2486246376, G249311083, G2585684547, Modulation of Mitofusin Activity to Treat Heart Disease, G280444578, G281933567, G2836354684, G2940288175, A paradigm-shifting idea in storage-disease cardiomyopathy, G3074976661, G3672453180, Einstein-Montefiore Clinical and Translational Science Award Hub, G3913092241, G4073434654, Caspase-9 as a nodal point connecting necrotic and apoptotic cell death in myocardial infarction, Mechanisms of cardiovascular disease, G425922058, G4480553772, G4480573366, G464942673, CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patients, G522617745, G5277196867, G5298350625, G531307636, G5423166509, G564856328, G6133271709, G6295426566, A Novel Strategy Against Cardiotoxicity, G6505368759, G671159905, G6737277850, G7029817771, G7492960808, G7661411873, G7854002418, G790170206, G802470759, G8134671829, G8224181935, Purposeful Outreach for Diversity and Inclusion of Underrepresented in Medicine (PODIUM) Physician-Scientists, G8385843488, G8445767824, G8551577206, G864706750, G873634175, G8970445542, G9000020154, G9000023692, G9000032473, G9000036909, G9000045154, G9000045632, G9000148014, G9000203699, G9000291687, G968247314, G970016019, G981417163
OpenAlex ID: W4406761610